Cellebrite DI Ltd. Global Chief Revenue Officer Marcus Jewell filed a Form 144 on November 10, 2026, notifying the SEC of a proposed sale of 1,045 ordinary shares on approximately November 12, 2026, following the vesting of restricted share units.

Key Highlights

  • Seller and role: Marcus Jewell, Global Chief Revenue Officer of Cellebrite DI Ltd. (NASDAQ:CLBT), filed the notice.
  • Shares proposed for sale: 1,045 ordinary shares with an aggregate market value of $13,271.50, with an approximate sale date of November 12, 2026.
  • Source of shares: The 1,045 shares were acquired on November 11, 2026, through restricted share units vested under an issuer S-8 registered plan, as employee compensation.
  • Purpose of sale: According to the filing, the sale is pursuant to "a mandatory, non-discretionary, sell-to-cover arrangement for the purposes of satisfying income tax liabilities incurred upon vesting of restricted share unit awards only."
  • Shares outstanding: 251,341,060 ordinary shares were reported outstanding at the time of filing.
  • Prior sales in past 3 months: Jewell sold 411 shares on August 12, 2026 for gross proceeds of $6,603.86, and 12,562 shares on August 21, 2026 for gross proceeds of $141,216.97.

Jewell's Tax-Driven RSU Sell-to-Cover at Cellebrite DI

According to the Form 144 filing, Marcus Jewell, serving as Global Chief Revenue Officer of Cellebrite DI Ltd., proposed selling 1,045 ordinary shares of Cellebrite common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. The filing states that shares were to be sold on approximately November 12, 2026, with an aggregate market value reported as $13,271.50.

The filing discloses that the 1,045 shares were acquired on November 11, 2026, from Cellebrite DI Ltd. through restricted share units vested under an issuer S-8 registered plan, with the nature of payment described as employee compensation. Jewell noted in the Remarks section that the proposed sale is pursuant to "a mandatory, non-discretionary, sell-to-cover arrangement for the purposes of satisfying income tax liabilities incurred upon vesting of restricted share unit awards only."

The filing also reports Jewell's sales activity over the prior three months. On August 12, 2026, Jewell sold 411 shares of common stock for gross proceeds of $6,603.86, and on August 21, 2026, sold 12,562 shares for gross proceeds of $141,216.97. The total shares outstanding at the time of filing were listed as 251,341,060.

What Was Disclosed

Cellebrite DI Ltd. officer Marcus Jewell filed a Form 144 on November 10, 2026, disclosing a proposed sale of 1,045 ordinary shares valued at $13,271.50, acquired through RSU vesting, intended to cover associated income tax liabilities.